



FOR IMMEDIATE RELEASE

Xeris Pharmaceuticals Announces New Scientific Advisory Board Member, Dr. Ken Ward

AUSTIN, TX – June 26, 2012 – Xeris Pharmaceuticals, Inc. (“Xeris”) announces today that Dr. Ken Ward will join the company’s Scientific Advisory Board (SAB) effective immediately. A highly-regarded endocrinologist and diabetologist, Dr. Ward’s primary research interests are blood glucose management and artificial pancreas systems. As the SAB’s newest member, Dr. Ward will bring his expertise in the development of the artificial pancreas/bi-hormonal pump and collaborate on a project with Xeris on the development of stable glucagon formulations.

Dr. Ward currently serves as Associate Professor in the Division of Endocrinology, Metabolism and Clinical Nutrition at the Oregon Health and Science University (OHSU) and as Senior Scientist at the Legacy Research Institute, the research arm of the Legacy Health System. Both institutions are located in Portland, OR. At Legacy, he is the Principal Investigator of the Diabetes Research Laboratory, and, with his research team, has developed an automated system for controlling glucose levels designed to be used in patients with Type 1 diabetes.

His focus on developing an automated closed-loop device aligns with Xeris’ products under development including, in the long term, a bi-hormonal pump with glucagon on-board. For patients with diabetes, severe hypoglycemia (low blood sugar), can be life-threatening. “By administering a chemically stable glucagon through a portable pump, we would likely prevent most of these episodes,” remarks Ward. “The team at Xeris has invented a chemistry method that avoids glucagon’s spontaneous degradation and this method has the potential for making life better and safer for people with diabetes.”

Dr. Steve Prestrelski, Xeris’ Chief Scientific Officer, noted that “Dr. Ward’s experience in blood glucose management, his knowledge of glucose sensors and hypoglycemia will be invaluable in developing a bi-hormonal pump with stable glucagon on board. We are especially excited about the prospect of working with him to research the effects of a stable, non-aqueous glucagon in these closed-loop systems.”

Dr. Ward received his M.D. degree from the University of Colorado, School of Medicine in 1978 and completed an internal medicine residency prior to performing a research fellowship at the University of Washington in Seattle.

About Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Austin, Texas. Xeris develops injectable therapeutics to treat endocrine and metabolic diseases, as well as therapeutics for indications in neurology and immunology. Its low-volume and ready-to-use pharmaceuticals provide convenient and

patient-friendly devices through the subcutaneous delivery of concentrated, non-aqueous pastes or liquid drug formulations. Its delivery technologies will eliminate reconstitution of biologics, simplify administration, and ease the pain of injections for millions of patients and caregivers. For more information please visit the Xeris website at: www.xerispharma.com

###

Media Contact

Saretta Ramdial

Xeris Pharmaceuticals, Inc.

+(1) 512-947-2801

sramdial@xerispharma.com

www.xerispharma.com